Patrick C Ma MD MSc

Thoracic Cancer

Professor of Medicine and Microbiology & Immunology, Interim Chief of Division of Hematology and Medical Oncology, Associate Director of Translational Research, Thoracic Oncology Multidisciplinary Disease Team leader, Co-leader of Next Generation Therapies Program

Join to View Full Profile

Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center500 University Drive, P.O. Box 850, Mail Code CH46Hershey, PA 17033
Phone+1 717-531-8870
Fax+1 717-531-5076

Education & Training

Dana-Farber Cancer InstituteFellowship, Thoracic Oncology Research, 2001 - 2003
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
St Elizabeth's Medical CenterResidency, Internal Medicine, 1996 - 1999
Toronto General HospitalResidency, C.C.F.P., 1994 - 1996
University of Toronto Faculty of MedicineClass of 1994

Certifications & Licensure

PA State Medical License 2019 - 2026
WV State Medical License 2015 - 2021
OH State Medical License 2005 - 2016
IL State Medical License 2003 - 2005
MA State Medical License 1996 - 2005

Awards, Honors, & Recognition

Best Doctors (Medical Oncology) Cleveland Magazine, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Start of enrollment: 2016 Apr 10
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC Start of enrollment: 2020 Mar 09
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.
Utsav Sen, Charles Coleman, Nishant Gandhi, Vrinda Jethalia, Deniz Demircioglu
Cancer Research. 2025-04-08
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Narjust Florez, Sandip P Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli
The Oncologist. 2025-02-06
Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.
Zuan-Fu Lim, Xiaoliang Wu, Lin Zhu, Heidar Albandar, Maria Hafez
Translational Lung Cancer Research. 2024-12-31

Lectures

Novel Platforms and Clinical Applications for Noninvasive Molecular Testing
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Penn State Cancer Institute Joins Caris Life Sciences' Precision Oncology AllianceAugust 25th, 2020
‘Cancer-Agnostic’ NTRK Inhibitor Approval Ushers in Paradigm of Personalized Genomics-Guided TherapeuticsJanuary 10th, 2019
Mesothelioma Clinical Trial Opens with High ExpectationsJune 16th, 2017